MODERN POSSIBILITIES OF THERAPEUTIC CORRECTION OF ANTIPSYCHOTICS-INDUCED HYPERPROLACTINEMIA

Abstract

Hyperprolactinemia (GPRL) is one of the most common side effects when prescribing antipsychotic therapy. GPRL is obviously a significant problem in psychiatric clinical practice. A significant
effect of increasing prolactin levels on the somatic state of patients, as well as on the course of the disease process, necessitates a change in treatment tactics to correct GPRL. Currently,
methods have been developed to reduce prolactin levels with the use of antipsychotics.
The purpose of this article is to evaluate current therapeutic options for reducing the negative effects of antipsychotics<induced hyperprolactinemia. Correction methods associated with
the use of additional drugs that reduce prolactin levels, or correcting the clinical manifestations of increased prolactin are currently being studied and there is no convincing data on their
safety in this category of patients. The most acceptable and having a real broad perspective in everyday clinical practice approach is the replacement of antipsychotics with a drug with less
prolactogenic activity.
The data presented in the article on the lesser prolactogenic activity of prolonged forms of second<generation antipsychotics open up new perspectives in the correction of antipsychotics<
induced hyperprolactinemia when the active substance does not change, but only the administration form, which makes it possible to assume a decrease in the risks associated with drug
replacement.